Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock
SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) — Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq:LAB) today announced that it has exchanged all outstanding shares of its Series B Convertible Preferred Stock (the “Series B Preferred”) for shares of common stock pursuant to an agreement with stockholders affiliated with Viking Global Investors (“Viking”) and Casdin Capital (“Casdin”).